Fumio Yoneda

USPTO Granted Patents = 11 (Patent Applications = 2)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 32(Granted Patents)

Location History:

Matsubara, JP (1998 - 2013)
Osaka, JP (2001 - 2017)

Company Filing History:

Fujimoto Brothers Co., Ltd.

Fujimoto Pharmaceutical Co., Ltd.

patent

where one patent can have more than one assignee

Years Active: 1998-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9782383 - Prophylactic and therapeutic agent for attention-deficit/hyperactivity disorder (2017-10-10),

2. 8512744 - Sustained release micropellets and process for producing the same (2013-08-20),

3. 8318799 - Therapeutic agent for substance dependence (2012-11-27),

4. 8178686 - Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate (2012-05-15),

5. 7825158 - Therapeutic agent for substance dependence (2010-11-02),

6. 7807840 - Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate (2010-10-05),

7. 6667328 - Therapeutic agents for diabetes (2003-12-23),

8. 6391914 - Optically active aminopentane derivatives (2002-05-21),

9. 6380229 - 2-(N-cyanoimino)thiazolidin-4-one derivatives (2002-04-30),

10. 6214859 - Ethylamine derivatives (2001-04-10),

11. 5739117 - Agent for improving cerebral metabolism including glucose ester (1998-04-14),

Title: Fumio Yoneda: Innovator in Pharmaceutical Development

Introduction

Fumio Yoneda is a notable inventor based in Matsubara, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for attention-deficit/hyperactivity disorder (ADHD). With a total of 11 patents to his name, Yoneda's work has had a profound impact on medical science.

Latest Patents

One of his latest patents is a prophylactic and therapeutic agent for ADHD. This invention reveals that 1-(benzofuran-2-yl)-2-propylaminopentane, or its pharmacologically acceptable acid addition salt, is effective in preventing and treating ADHD. This discovery adds to the compound's known benefits as an antidepressant, psychotropic drug, antiparkinsonian drug, and anti-Alzheimer's disease drug. Another significant patent involves sustained release micropellets, which provide stable controlled-release of a drug, unaffected by changes in pH. These micropellets are produced by coating core particles with a water-soluble drug layer and forming a film layer with a water-insoluble polymer compound and a plasticizer.

Career Highlights

Fumio Yoneda has worked with several companies throughout his career, including Fujimoto Co., Ltd. and Fujimoto Brothers Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.

Collaborations

Throughout his career, Yoneda has collaborated with notable individuals such as Mayumi Watanabe and Hironori Ohde. These partnerships have likely enhanced his research and development efforts.

Conclusion

Fumio Yoneda's contributions to the field of pharmaceuticals, particularly in ADHD treatment and drug delivery systems, highlight his innovative spirit and dedication to improving medical outcomes. His work continues to influence the industry and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.